Yes, cheaper diagnostic tests could meaningfully reduce reliance on PET scans for dementia evaluation, though they would likely function as initial screening tools rather than complete replacements. PET scans remain expensive—typically costing $5,000 to $7,000 per scan—and insurers increasingly scrutinize their use. Emerging blood biomarker tests that cost $150 to $500 per test can now detect Alzheimer’s pathology before cognitive symptoms appear, offering a less expensive pathway for early identification.
For example, a 65-year-old with family history and mild memory complaints might first receive a blood test for phosphorylated tau or amyloid levels; if results are abnormal, a PET scan could then confirm findings and inform treatment decisions, rather than jumping directly to expensive imaging. The shift toward cheaper alternatives reflects a broader change in how neurology and geriatrics approach dementia diagnosis. Insurance companies, Medicare, and healthcare systems recognize that not every patient needs advanced imaging, and the financial burden of PET scans can delay or prevent evaluation in patients without ready access to specialized centers.
Table of Contents
- What Blood Tests Can Tell Us That Justifies Skipping Initial PET Scans
- Cost Barriers and Why Cheaper Alternatives Matter in Practice
- How Blood Biomarkers Are Changing Who Gets PET Scans and When
- When Cheaper Tests Fall Short: Tradeoffs and Practical Limits
- Limitations of Blood Tests and Why Imaging Still Defines Dementia Workup
- Insurance Coverage and Access: Who Benefits from Cheaper Alternatives
- How Cognitive Screening and Blood Biomarkers Are Now the Standard Starting Point
What Blood Tests Can Tell Us That Justifies Skipping Initial PET Scans
Blood biomarkers have moved from research tools to clinical reality over the past three years. Tests measuring phosphorylated tau-181, phosphorylated tau-217, amyloid-beta 42, and neurofilament light chain can now be ordered through mainstream labs and insurance often covers them, especially when ordered by a neurologist or geriatrician. These tests don’t require a scanner, radioactive tracers, or a specialized facility. A patient can have blood drawn in their primary care office and results returned within days. The clinical value is substantial: abnormal blood biomarkers predict which patients have underlying Alzheimer’s pathology even if they have no symptoms or only very mild cognitive changes.
However, blood tests measure different things than PET scans do. A positive blood biomarker indicates that amyloid or tau pathology exists in the brain—a necessary finding for Alzheimer’s disease—but it does not show the *location* or *distribution* of that pathology. PET scans provide spatial maps. A 70-year-old with abnormal tau blood markers might have tau concentrated in the temporal lobe (suggesting frontotemporal dementia) or spread across multiple regions (suggesting Alzheimer’s), and that distinction matters for prognosis and treatment. This is why many specialists view blood tests as gatekeepers: they answer the yes/no question of whether pathology exists, and PET imaging provides the architecture of that pathology.
Cost Barriers and Why Cheaper Alternatives Matter in Practice
A patient without insurance, or with insurance that requires high out-of-pocket costs for imaging, may wait months or skip imaging entirely rather than face a $5,000 bill. In rural areas, the nearest pet imaging center might require traveling hours. A blood test that costs $200 and is available at local labs removes these barriers for the initial step of evaluation. Insurance companies have begun recognizing this: Medicare now covers blood biomarker tests for cognitive decline, and many commercial insurers have followed.
The shift has accelerated partly because blood tests are so much cheaper that even covering them broadly costs less than covering all the PET scans that were being ordered as first-line imaging. Yet there is a real risk of oversimplifying the diagnosis pathway. Some patients with cognitive symptoms will have abnormal blood biomarkers that do not yet explain their symptoms—perhaps they have preclinical Alzheimer’s pathology but are experiencing cognitive changes from a different cause, like B12 deficiency or medication side effects. Skipping further evaluation because a blood test came back abnormal can lead to missed alternative diagnoses. Additionally, blood biomarker tests are newest for amyloid and tau; markers for other dementias like Lewy body disease or vascular dementia are less established, so a “normal” blood biomarker panel doesn’t rule out non-Alzheimer’s causes of cognitive decline.
How Blood Biomarkers Are Changing Who Gets PET Scans and When
Five years ago, a patient with subjective memory complaints might be referred for PET imaging without any biomarker testing—it was the way to confirm or rule out Alzheimer’s pathology. Now, that same patient is more likely to have blood tests first. If results are negative, the patient is reassured and may not need imaging. If results are positive but cognitive testing is normal or shows only mild changes, the patient might be monitored with repeat blood tests rather than immediately sent for PET. If blood biomarkers are positive and the patient has clear cognitive decline, PET becomes appropriate to map the distribution of pathology and look for co-pathology (such as amyloid and tau together, or either one alongside Lewy bodies). This tiered approach saves money and radiation exposure.
A concrete example: a 72-year-old woman reports to her neurologist that she’s been forgetting names and misplacing items, concerns that began about 18 months ago. Cognitive testing shows she’s at the edge of normal. Ten years ago, she would have received a PET scan as the next step—cost, $6,000. Today, she’ll have blood biomarkers drawn. If they’re negative, that’s reassuring; if positive but mild, she might repeat testing in 6 months rather than proceed to PET immediately. The cheaper blood test has become the gatekeeper, and imaging is reserved for cases where the clinical picture is more complex or the stakes of uncertainty are higher.
When Cheaper Tests Fall Short: Tradeoffs and Practical Limits
Cheaper blood tests cannot replace PET imaging for all situations. A patient with atypical cognitive symptoms—such as progressive difficulty with language or visual-spatial skills while memory is intact—might have primary progressive aphasia or posterior cortical atrophy, conditions where the *location* of brain pathology matters enormously for diagnosis. Blood biomarkers might be abnormal, but they won’t tell you whether the tau is concentrated in the left temporal lobe or spread across both hemispheres. That requires imaging.
Similarly, blood tests are less sensitive for detecting Lewy body pathology; they measure tau and amyloid but not alpha-synuclein, so a patient suspected of Lewy body dementia may still need PET (or other imaging like DaT scan) despite normal blood work. Cost is deceptive in another way. If a blood test creates uncertainty that leads a patient and family through multiple follow-up visits, repeated blood draws, and specialist consultations before a PET scan is finally ordered, the total cost may not be lower—just delayed. And waiting matters when a patient is declining. A 68-year-old with clear cognitive decline and imaging-dependent treatment decisions might be better served by going straight to PET rather than spending three months and multiple office visits on biomarker panels that will likely be abnormal anyway.
Limitations of Blood Tests and Why Imaging Still Defines Dementia Workup
Blood biomarkers are not yet standardized across all labs, and reference ranges differ. A result that’s “abnormal” at one facility might be reported as “borderline” at another. This variability is improving but hasn’t been fully resolved, meaning clinicians still need experience and specialist judgment to interpret results. Also, blood biomarkers do not distinguish between different types of pathology equally.
Phosphorylated tau-181 is highly sensitive for Alzheimer’s pathology, but the test can be falsely elevated in other conditions; amyloid and tau can coexist in brains of cognitively normal older adults, especially after age 80. None of these tests tell you whether the person will decline, how quickly, or whether they need treatment right now. Furthermore, blood biomarker testing requires a clear clinical indication and appropriate specialist ordering to be covered by insurance. A patient who sees only their primary care doctor may be unable to access these tests or may have them refused by insurance as “experimental” (coverage varies by payer and region). The shift toward cheaper blood tests is real but not universal, leaving many patients in areas with less sophisticated healthcare access still relying on imaging as the default diagnostic pathway.
Insurance Coverage and Access: Who Benefits from Cheaper Alternatives
Medicare coverage of blood biomarker tests for cognitive decline began in 2022, but commercial insurance coverage remains inconsistent. Some plans cover the tests readily; others require prior authorization or deny them as not medically necessary. This creates a two-tier system: patients in well-resourced healthcare systems and those with good insurance access benefit from the cheaper pathway, while others do not.
A patient in a major medical center who sees a cognitive neurologist can access blood biomarkers quickly; the same patient in a rural area seeing their primary care doctor may not. Rural and underserved communities are hit harder by the reliance on expensive PET scans because distance and transportation are additional barriers. A blood test can be done locally, but if PET imaging is still the default diagnostic method in that region, a positive blood biomarker still requires travel to a regional center. Conversely, if blood tests become the standard first-line tool, patients in rural areas gain easier access to diagnostic workup without needing to travel.
How Cognitive Screening and Blood Biomarkers Are Now the Standard Starting Point
The current standard of care in academic medical centers and specialty practices is to begin with cognitive screening (such as the Montreal Cognitive Assessment or Mini-Cog) combined with blood biomarkers before considering imaging. This approach emerged over the past 2–3 years as blood biomarker tests became widely available and insurance began covering them. A patient referred for cognitive evaluation now typically receives cognitive testing and blood biomarkers at the first visit. Results are reviewed at a follow-up visit, and imaging is recommended only if it will change management or if the clinical picture is complex enough to require spatial mapping of pathology.
Neuropsychological testing—a detailed, multi-hour assessment of memory, executive function, language, and other domains—often follows cognitive screening if there’s concern about cognitive decline. This testing costs $1,000 to $2,000 and is more sensitive for detecting mild decline than brief office-based testing, but it’s still far cheaper than PET imaging. Together, cognitive screening, blood biomarkers, and neuropsychological testing provide a much more complete picture than PET imaging alone could, and at a fraction of the total cost. For a patient with memory complaints, starting with these three modalities—all of which are now standard—identifies the vast majority of cases requiring advanced imaging and those that need alternative diagnoses investigated instead.
